Table 1.
Overview of the patient cohort. Clinical and laboratory data of the 33 patients included in this study.
| Number of patients (%) | Data availability (%) | |
|---|---|---|
| Oligoarthritis, persistent | 28 (85) | 33 (100) |
| Oligoarthritis, extended | 5 (15) | 33 (100) |
| Sex, female | 25 (76) | 33 (100) |
| NSAID | 22 (67) | 33 (100) |
| Uveitis | 4 (12) | 32 (97) |
| ANA-positive | 25 (76) | 33 (100) |
| Anti-CCP-positive | 0 (0) | 24 (73) |
| RF-positive | 0 (0) | 24 (73) |
| Median (IQR) | Data availability (%) | |
| §Disease duration, months | 8 (84) | 33 (100) |
| #Age, years | 11 (6.5) | 33 (100) |
| Active joint count | 1 (1) | 33 (100) |
| Blood WBC (106/ml) | 6.49 (2.03) | 25 (76) |
| SF WBC (106/ml) | 4.01 (3.93) | 26 (79) |
§Disease duration at time of sampling. #Age at time of diagnosis; ANA, Anti-nuclear antibodies; NSAID, Non-steroidal anti-inflammatory drugs; CCP, Cyclic citrullinated peptide; RF, Rheumatoid factor; WBC, White blood cells; SF, Synovial fluid.